106 related articles for article (PubMed ID: 93529)
1. Modulatory effects of oestrogen on immunological responsiveness. II. Suppression of tumour-associated immunity in patients with prostatic cancer.
Ablin RJ; Bhatti RA; Guinan PD; Khin W
Clin Exp Immunol; 1979 Oct; 38(1):83-91. PubMed ID: 93529
[TBL] [Abstract][Full Text] [Related]
2. Further evaluation of the effect of estrogen on tumor-associated immunity in prostatic cancer.
Ablin RJ; Bhatti RA; Guinan PD
Isr J Med Sci; 1979 Jan; 15(1):9-11. PubMed ID: 422345
[TBL] [Abstract][Full Text] [Related]
3. Effect of estrogen on tumor-associated immunity in patients with adenocarcinoma of the prostate.
Ablin RJ; Bhatti RA; Guinan PD
Cancer Res; 1978 Nov; 38(11 Pt 1):3702-6. PubMed ID: 698929
[TBL] [Abstract][Full Text] [Related]
4. Modulatory effects of oestrogen on immunologic responsiveness. I. Inhibition of DNA synthesis in peripheral blood lymphocytes from patients with Peyronie's disease, prostatic cancer and transsexuals and a commentary.
Ablin RJ; Bruns GR; Guinan PD; Al Sheik H; Bush IM
Eur Urol; 1979; 5(6):359-68. PubMed ID: 467472
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulatory effects of oestrogen in prostatic cancer: update and further consideration.
Ablin RJ
Allergol Immunopathol (Madr); 1981; 9(1):63-70. PubMed ID: 7258047
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of cellular immunologic responsiveness in the clinical management of patients with prostatic cancer. II. Effect of oestrogen, cryosurgery and transurethral resection on thymic-dependent lymphocytic blastogenesis.
Ablin RJ; Guinan PD; Bruns GR; Sheik HI; Sadoughi N; Bush IM
Urol Int; 1976; 31(5):383-400. PubMed ID: 1087494
[TBL] [Abstract][Full Text] [Related]
7. Leuprolide vs. diethylstilboestrol: effect on natural killer cells.
Ablin RJ; Gonder MJ; Bartkus JM
Anticancer Res; 1988; 8(1):73-6. PubMed ID: 3128959
[TBL] [Abstract][Full Text] [Related]
8. Tumor-associated immunity in prostatic cancer as evaluated by tube antigen-induced leukocyte adherence inhibition: reactivity and specificity of responsiveness, and relationship to stage, grade and therapy.
Bhatti RA; Ablin RJ; Guinan PD
J Reticuloendothel Soc; 1979 Apr; 25(4):389-95. PubMed ID: 458777
[No Abstract] [Full Text] [Related]
9. Cell-mediated immunity in prostatic cancer.
Ablin RJ; Bhatti RA; Nagubadi S; Zamora S; Guinan PD
Clin Oncol; 1980 Sep; 6(3):253-64. PubMed ID: 7428203
[No Abstract] [Full Text] [Related]
10. Hormonal therapy and alterations of immunity in prostatic cancer.
Ablin RJ
Neoplasma; 1981; 28(3):345-50. PubMed ID: 7290262
[TBL] [Abstract][Full Text] [Related]
11. Effect of diethylstilboesterol diphosphate on tumour-assoiciated immunity in prostatic cancer. A preliminary report.
Bhatti RA; Ablin RJ; Guinan PD; Totonchi E; Zamora S
Experientia; 1978 Oct; 34(10):1364-5. PubMed ID: 738427
[No Abstract] [Full Text] [Related]
12. Hormonal therapy and alteration of lymphocyte proliferation.
Ablin RJ; Bruns GR; Guinan PD; Al sheik H; Bush IM
J Lab Clin Med; 1976 Feb; 87(2):227-31. PubMed ID: 1245789
[TBL] [Abstract][Full Text] [Related]
13. Effect of human seminal plasma on tumour-associated immunity in patients with adenocarcinoma of the prostate.
Ablin RJ; Bhatti RA; Bush IM; Guinan PD
J Reprod Immunol; 1980 Feb; 1(5-6):337-45. PubMed ID: 7411523
[TBL] [Abstract][Full Text] [Related]
14. Possible suppression of host resistance by estrogen therapy for prostatic cancer.
Ablin RJ
Can Med Assoc J; 1976 Dec; 115(11):1082-4. PubMed ID: 1000436
[TBL] [Abstract][Full Text] [Related]
15. Cell-mediated antitumor immunity in breast cancer patients evaluated by antigen-induced leukocyte adherence inhibition in test tubes.
Grosser N; Thomson DM
Cancer Res; 1975 Sep; 35(9):2571-9. PubMed ID: 1097110
[TBL] [Abstract][Full Text] [Related]
16. The immunotherapy of prostate and bladder cancer.
Totterman TH; Loskog A; Essand M
BJU Int; 2005 Oct; 96(5):728-35. PubMed ID: 16144528
[TBL] [Abstract][Full Text] [Related]
17. [Cellular immunity in prostatic cancer modified by Cytonal, Estrazyt and Turisteron].
Klebingat KJ; Panzig E; Lorenz G; Steinhauser I; Fiedler R
Z Urol Nephrol; 1987 Mar; 80(3):139-47. PubMed ID: 3300097
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of disease flare with diethylstilbestrol diphosphate and chlormadinone acetate administration for two weeks prior to slow-releasing leuprolide acetate in prostatic cancer patients.
Ohuchi H; Noguchi K; Kinoshita Y; Hosaka M; Kawasaki C; Miura T; Kondo I; Harada M
Hinyokika Kiyo; 2000 Aug; 46(8):531-6. PubMed ID: 11019371
[TBL] [Abstract][Full Text] [Related]
19. Modulatory effects of estrogen on immunologic responsiveness. III. Effect of hormonal versus nonhormonal therapy on tumor-associated immunity in prostatic cancer.
Ablin RJ
Am J Reprod Immunol (1980); 1981 Aug; 1(4):206-9. PubMed ID: 7337156
[TBL] [Abstract][Full Text] [Related]
20. Preliminary report of an immunological study in urological cancer.
Serrallach N; Jimenez JF; Aguiló F; Anguera A; Clavo M; Orejas V; Torner V; Serrate R
Eur Urol; 1975; 1(2):99-100. PubMed ID: 1241896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
